FWP
CBIO

Firethorn Wealth Partners’s Crescent Biopharma CBIO Stock Holding History

Firethorn Wealth Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-117
Closed -$2.46K – 183
2025
Q1 		$2.46K Buy
+117
New +$3.13K ﹤0.01% 172

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Firethorn Wealth Partners's CBIO Position: Q2 2025 in Review

Firethorn Wealth Partners sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 117 shares — an estimated $2.46K sold.

Firethorn Wealth Partners first reported a position in CBIO in Q1 2025 and held it in 1 quarter. The position peaked at $2.46K in Q1 2025. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Firethorn Wealth Partners reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Firethorn Wealth Partners sold 117 Crescent Biopharma shares in Q2 2025, an estimated $2.46K.
  • Firethorn Wealth Partners first reported a position in Crescent Biopharma in Q1 2025 and held it in 1 quarter.
  • Firethorn Wealth Partners's Crescent Biopharma position peaked at $2.46K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Firethorn Wealth Partners's 13F filing for Q2 2025, filed 22 Jul 2025.